Last edition
News about "Rare Disease Pipeline"
AstraZeneca Advances Rare Disease Pipeline with Positive HPP Phase III Data
Alexion, AstraZeneca Rare Disease, has reported positive results from its global Phase III clinical programme evaluating efzimfotase alfa (ALXN1850) in patients with hypophosphatasia (HPP), a rare inherited metabolic disorder.
Rare Disease Pipeline | 01/04/2026 | By Darshana | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members